HRMY - NASDAQ
Harmony Biosciences Holdings, Inc.
$32.10
+0.91%Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
At a Glance
Live SnapshotHarmony Biosciences Holdings, Inc. Management Team
Ms. Tricia Glover
Chief Compliance Officer
Ms. Audrey Murphy SPHR
Chief Human Resources Officer
Mr. Andrew Serafin J.D., M.B.A.
Executive Vice President & Chief Strategy Officer
Compensation
$791,404
Dr. Kumar Budur M.D., M.S.
Executive Vice President and Chief Medical & Scientific Officer
Compensation
$773,801
Mr. Sandip S. Kapadia CPA, M.B.A.
Executive Vice President, Chief Administrative Officer & Chief Financial Officer
Compensation
$1,064,327
Mr. Jeffrey S. Aronin
Founder & Non-Executive Chairman
Compensation
$40,000
Mr. Christian Ulrich J.D.
General Counsel & Corporate Secretary
Dr. Jeffrey M. Dayno M.D.
President, Chief Executive Officer & Director
Compensation
$1,666,683
Ms. Cate McCanless
Senior Vice President & Chief Corporate Affairs Officer
Brennan Doyle
Vice President & Head of Investor Relations
Harmony Biosciences Holdings, Inc. Insider Positioning
During the last 12 months, insiders have sold $2.83M worth of HRMY shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
30.6K
1.13M
-1.1M
-$1.13M
6-9 Months
0
0.00
23.4K
910.84K
-911K
-$911K
9-12 Months
0
0.00
21.6K
787.38K
-787K
-$787K
Top Buyers
No buying activity
Top Sellers
Kapadia Sandip
Officer: Chief Financial Officer
$2.59M
Dayno Jeffrey M.
Director, Officer: President, Ceo
$238K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $2.83M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
HRMY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | May 14, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 04, 2025 | May 15, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 11, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 14, 2023 | April 14, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 08, 2022 | May 20, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 09, 2021 | May 20, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.